Diabetes mellitus (DM) and heart failure (HF) are comorbid conditions
associated with significant morbidity and mortality worldwide. Despite
the availability of novel and effective therapeutic options and
intensive glycaemic control strategies, mortality and hospitalisation
rates continue to remain high and the incidence of HF persists. In this
review, we described the impact of currently available glucose-lowering
therapies in DM with a focus on HF clinical outcomes. Non-conventional
modes of management and alternative pathophysiological mechanisms with
the potential for therapeutic targeting are also discussed
